Xosé R. Bustelo
Centro de investigación del Cáncer (CIC), Salamanca, Spain
Dr. Xosé R. Bustelo is a Full Research Professor at the Spanish National Research Council (Consejo Superior de Investigaciones Científicas, CSIC), the main scientific institution of the Spanish central government. He also holds a principal investigator position at the Cancer Biomedical Research Center (Centro de Investigación Biomédica en Red de Cáncer, CIBERONC), a Spanish government–sponsored multicenter initiative aimed at promoting cooperative work in both basic and clinical research among the 50 top–rated cancer labs in Spain.
Dr. Bustelo’s scientific training includes a Ph.D. in Biology from the University of Santiago de Compostela (Galicia, Spain, 1990) and a postdoctoral stint at the Bristol–Myers Squibb Pharmaceutical Research Institute (Princeton, NJ, USA; years 1990–1993). He then worked as Staff Scientist at the Bristol–Myers Squibb Pharmaceutical Research Institute (Princeton, NJ, USA; years 1993-1996), as Assistant Professor at the Department of Pathology of the State University of New York at Stony Brook (Stony Brook, NY, USA; years 1996–2000) and, subsequently, as both CSIC Tenured (1999–2004) and Senior Research (2004–2005) scientist at the Cancer Research Center (Centro de Investigación del Cáncer, CIC) of Salamanca (Spain).
Dr. Bustelo’s work has been traditionally focused on the understanding of signal transduction processes initiated by Rho GTPases during both physiological and pathological conditions. His group has made key findings on the regulation of these proteins, the isolation of upstream GTPase regulators, and the elucidation of the role of these proteins in normal physiological contexts and high–incidence pathologies such as cancer, cardiovascular disease, and metabolic syndrome.
In addition to the foregoing scientific activity, Dr. Bustelo is the Vice-Director of the CIC of Salamanca, the Director of the CIC Genomics and Proteomics Unit, a member of the CIBERONC Executive Committee and the coordinator of the CIBERONC Mechanisms of Tumor Progression Program. He is also an active member of a large number of advisory scientific committees and editorial boards.
Dr. Xosé R. Bustelo is a Full Research Professor at the Spanish National Research Council (Consejo Superior de Investigaciones Científicas, CSIC), the main scientific institution of the Spanish central government. He also holds a principal investigator position at the Cancer Biomedical Research Center (Centro de Investigación Biomédica en Red de Cáncer, CIBERONC), a Spanish government–sponsored multicenter initiative aimed at promoting cooperative work in both basic and clinical research among the 50 top–rated cancer labs in Spain.
Dr. Bustelo’s scientific training includes a Ph.D. in Biology from the University of Santiago de Compostela (Galicia, Spain, 1990) and a postdoctoral stint at the Bristol–Myers Squibb Pharmaceutical Research Institute (Princeton, NJ, USA; years 1990–1993). He then worked as Staff Scientist at the Bristol–Myers Squibb Pharmaceutical Research Institute (Princeton, NJ, USA; years 1993-1996), as Assistant Professor at the Department of Pathology of the State University of New York at Stony Brook (Stony Brook, NY, USA; years 1996–2000) and, subsequently, as both CSIC Tenured (1999–2004) and Senior Research (2004–2005) scientist at the Cancer Research Center (Centro de Investigación del Cáncer, CIC) of Salamanca (Spain).
Dr. Bustelo’s work has been traditionally focused on the understanding of signal transduction processes initiated by Rho GTPases during both physiological and pathological conditions. His group has made key findings on the regulation of these proteins, the isolation of upstream GTPase regulators, and the elucidation of the role of these proteins in normal physiological contexts and high–incidence pathologies such as cancer, cardiovascular disease, and metabolic syndrome.
In addition to the foregoing scientific activity, Dr. Bustelo is the Vice-Director of the CIC of Salamanca, the Director of the CIC Genomics and Proteomics Unit, a member of the CIBERONC Executive Committee and the coordinator of the CIBERONC Mechanisms of Tumor Progression Program. He is also an active member of a large number of advisory scientific committees and editorial boards.
